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466a Tuesday, March 8, 2011of Ca2þ, dissociation of CaM from C28 occurs by a pathway in which Trp
1093, although deeply embedded in a pocket in the C-terminal lobe of
CaM, leaves first. The dissociation begins by relatively rapid release of Trp
1093, followed by very slow release of Phe 1110, removal of C28 and return
of CaM to its conformation in the free state. The intermediate of dissociation
with exposed Trp 1093 has a long lifetime (minutes), and is an activated form
of PMCA. This mechanism may explain some unique biological properties of
PMCA4b.
2522-Pos Board B508
Oligomeric Interactions of Sarcolipin and SERCA Detected by FRET
Microscopy
Joseph M. Autry, John E. Rubin, Seth L. Robia, David D. Thomas.
We have monitored molecular interactions of sarcolipin (SLN) and the sarco-
plasmic reticulum Ca- ATPase (SERCA) by measuring Fo¨rster resonance en-
ergy transfer (FRET) between fusion proteins labeled with cyan fluorescent
protein (donor) and yellow fluorescent protein (acceptor). SLN is a key mem-
brane protein that controls muscle contractility by regulating the calcium
transport activity of SERCA, and perhaps by also acting as an ATP-
activated anion channel (Becucci et al., Biophys. J. 2007, 2009). Here we
used baculovirus expression of fluorescent fusion proteins in insect cells
and FRET microscopy to provide novel evidence for (a) independent oligo-
merization of SLN and (b) regulatory complex formation between SERCA
and SLN. FRET assays demonstrated that SLN monomers self-assemble
into dimers and higher-order oligomers in the absence of SERCA, but that
SLN monomers also bind to SERCA in a 1:1 binary complex when the two
proteins are co-expressed. FRET assays further demonstrated that the binding
affinity of SLN:SLN homo-oligomers is greater than the binding affinity of
SERCA:SLN hetero-dimers, indicating that SLN monomers favor self-
association over SERCA binding. Mutating SLN residue isoleucine-17 to al-
anine (I17A) decreased FRET for SLN self-association and eliminated multi-
meric assembly of SLN, converting higher-order oligomers into monomers
and dimers. The I17A mutation also decreased FRET for SERCA:SLN
binding but maintained 1:1 stoichiometry of hetero-dimer formation. Thus,
isoleucine-17 is a residue that plays dual roles in (a) determining the distribu-
tion of SLN homo-oligomers and (b) stabilizing the formation of
SERCA:SLN hetero-dimers. When expressed in bacterial cells, wild-type
SLN prevented colony formation but the I17A-SLN mutant did not, indicating
that higher-order oligomers of SLN exhibit antibacterial activity, possibly
through channel formation. We propose that SLN exists as multiple molecular
species in muscle membranes, including SERCA-free (monomer, dimer, olig-
omer) and SERCA-bound (hetero-dimer).
2523-Pos Board B509
Identification of Phospholemman Residues Critical to Phospholemman
Oligomerization and Na Pump Association
Julie Bossuyt, Joseph C. Li, Mounir Khafaga, Linda L. Lee,
Luiza Mamikonian, Sanda Despa, Donald M. Bers.
Phospholemman (PLM or FXYD1) associates with and modulates Na pump
(NKA) function in a manner similar to phospholamban (PLB) regulation of
SERCA. That is, PLM inhibits NKA by reducing its [Na]i-affinity and PLM
phosphorylation relieves this inhibition. We have also shown that PLM forms
homo-oligomers (as does PLB) but it is unknown how PLM-PLM interactions
occur or what functional role PLM oligomers have. Here we use site-directed
mutagenesis and FRET to identify which PLM residues are critical to the
PLM-NKA and PLM-PLM association, respectively. We hypothesize that mu-
tations affecting PLM-PLM affinity will enhance PLM-NKA complexes and
display stronger NKA inhibition, and vice versa. Based on crystal NKA-
FXYD structure, the PLM sites G20, F28 & G31 were selected as potential
NKA interaction sites and I26, I29, L30, L33&L36 as putative PLM interac-
tion sites (analogous to leucine zippers thought to mediate PLB pentameriza-
tion). Alanine substitution of F28 eliminated PLM-NKA FRET (Fdonor
increase by only 0.254% vs 1852% for WT). Despite only minor effects
on PLM-NKA interaction for G31A (Fdonor increase by 1451%), its PLM-
PLM FRET was significantly increased (Fdonor increase by 5553% vs
3755% for WT). Alanine substitution of I26, L30 & L33 all significantly re-
duced PLM-PLM FRET (Fdonor increase by 1552%, 1353% and 2053% re-
spectively vs 3755% for WT) and opposing effects on PLM-NKA FRET
were observed (e.g. Fdonor increases by 3356% for L33A vs 1852% for
WT). We conclude that PLM homo-oligomers have a structural basis that par-
allels PLB (Leucine zipper). Moreover our hypothesis that altering the PLM
affinity for NKA also changes the interaction of PLM with other PLM mole-
cules (and vice versa) seems to be correct. Our data support the existence of
a dynamic equilibrium of PLM oligomers and PLM-NKA that exerts func-
tional regulation of NKA.2524-Pos Board B510
Highly Specific, Conformationally-Dependent Cross-Linking of Lys27 of
PLB to SERCA2a in Cardiac SR Vesicles from Humans
Brandy L. Akin, Larry R. Jones.
Phospholamban (PLB) inhibits SERCA2a, the Ca2þ-ATPase of cardiac sarco-
plasmic reticulum (SR), by decreasing the apparent Ca2þ affinity of the en-
zyme. The mechanism of Ca2þ pump inhibition by PLB has been studied by
our group using chemical cross-linking agents, which enable PLB-binding in-
teractions with SERCA2a to be measured simultaneously with enzyme inhibi-
tion. Previously, cross-linking of canine PLB to SERCA2a was only attainable
with Cys-scanning point mutants of PLB. For example, N27C of canine PLB
cross-links exclusively to Lys328 of canine SERCA2a with heterobifunctional
thiol-to-amine cross-linking agents after co-expression of the two proteins in
Sf21 insect cells. Here, we show with SR vesicles prepared from human hearts,
that PLB and SERCA2a are cross-linkable using DSG (disuccinimidyl gluta-
rate), a 7.7 A˚ long, homobifunctional, amine-specific cross-linking agent.
Cross-linking of human PLB to SERCA2a takes advantage of the unique Lys
residue at position 27 of human PLB, making it susceptible to amine-specific
cross-linkers without the need for mutagenesis. This was confirmed by testing
SR vesicles prepared from both human and canine ventricles; DSG cross-linked
human, but not canine, PLB to SERCA2a. Cross-linking of human PLB to
SERCA2a was completely inhibited by either Ca2þ (Ki = 0.50 mM), or the
Ca2þ pump inhibitor thapsigargin, but substantially augmented by ATP.
This is the first demonstration that PLB binds exclusively to the E2 conforma-
tion of SERCA2a in SR vesicles, preferentially the state with bound nucleotide
(E2$ATP), and not the state stabilized by thapsigargin (protonated E2). Impor-
tantly, similar results were obtained with SR vesicles prepared from both nor-
mal and failed human hearts, indicating that PLB-binding interactions with
SERCA2a are unchanged in failing myocardium. Studies are in progress to
demonstrate with human SR vesicles that Lys27 of PLB cross-links exclusively
to Lys328 of SERCA2a.
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Characterizing the Phospholamban-SERCA Complex by Pulsed EPR
Spectroscopy
Zachary M. James, Kurt D. Torgersen, Christine B. Karim,
David D. Thomas.
Muscle contraction and relaxation are controlled through the release and reup-
take of Ca2þ stored in the sarcoplasmic reticulum (SR). Relaxation is mediated
by the SR Ca2þ ATPase (SERCA), a pump that drives Ca2þ against its concen-
tration gradient while hydrolyzing ATP. Cardiac SERCA is regulated by phos-
pholamban (PLB), a small membrane protein that inhibits the pump except
when phosphorylated at Ser16. PLB phosphorylation restores SERCA activity
without dissociating the two proteins, instead inducing a structural change
within the PLB-SERCA complex. Although a number of studies have investi-
gated the interaction of these proteins, the relationship between phosphoryla-
tion, structure, and activity remains unresolved. We have used dipolar
electron-electron resonance (DEER) spectroscopy, a technique capable of mea-
suring distances from 2-7nm, to characterize large conformational changes
within PLB upon phosphorylation and SERCA binding. Our results show
that the transmembrane and cytoplasmic helices of PLB draw closer upon
SERCA binding, with subsequent phosphorylation compacting the structure
still further. However, relative distances between the cytoplasmic domains of
PLB and SERCA remain largely constant before and after phosphorylation,
suggesting that the observed structural change occurs in the transmembrane do-
main of PLB. Ultimately, our goal is to make exhaustive distance measure-
ments within the SERCA-PLB complex in order to understand the structural
basis of phosphorylation-mediated inhibition relief.
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StructuralDynamics ofSERCAandPhospholambanbyTR-FRETandTIRF
Ji Li, Christine Karim, David D. Thomas.
We used fluorescence to investigate the structure and dynamics of phospholam-
ban (PLB) and its inhibited target, sarcoplasmic reticulum Ca-ATPase
(SERCA). Time-resolved fluorescence energy transfer (TR-FRET) was used
to study the oligomeric interaction between PLB and SERCA. Previous work
on our lab has shown that PLB is primarily pentameric but SERCA binds pref-
erentially to the monomeric form in lipid vesicles. Recent EM studies suggest
that the PLB pentamer might also bind to SERCA.We tested this hypothesis by
labeling SERCA at C674 with a fluorescent donor (TMRIA) and labeling PLB
at K3 with a non-fluorescent acceptor (MGITC), then reconstituting the pro-
teins into lipid vesicles and performing TR-FRET as a function of the fraction
of acceptor-labeled PLB (xA), keeping the total PLB/SERCA molar ratio con-
stant at 10. Simulations showed that if a PLB monomer binds to SERCA, the
dependence of FRET on xA should be linear, but the binding of a PLB oligomer
